Background
Subsets of NSCLC carry alterations in the human epidermal growth factor receptor 2 (HER2) gene such as mutations (mt), amplification (amp), and protein overexpression. These alterations reflect distinct patient (pt) populations and disease biology, translating to variable outcomes with immunotherapy +/- chemotherapy. HER2-directed therapies have shown significant efficacy for HER2 mt and to a lesser extent HER2 overexpression NSCLC. We describe the genomic landscape of HER2-altered NSCLC in a large cohort of tumors from the Caris database and explore patient outcomes.